AstraZeneca's Lynparza Looks To Hang On To Lead, With Tesaro's Niraparib On The Way

Tesaro's niraparib has an advantage over other PARP inhibitors in that it has been tested successfully in ovarian cancer patients with and without BRCA mutations, but AstraZeneca thinks it may have a case for broad labeling in this population.